Keyphrases
Blood Samples
16%
CAPP-Seq
6%
Circulating Tumor DNA (ctDNA)
100%
Clinical Benefit
8%
Clinical Validity
8%
Commercially Available
14%
Commercially Available Kit
6%
Consolidation Therapy
6%
Contrast Detection
6%
Curative Intent
25%
Curative Treatment
33%
Deep Sequencing
14%
Disease Analysis
16%
DNA Analysis
6%
DNA Detection
8%
DNA Sequencing
50%
Fisher's Exact Test
12%
Log-rank Test
12%
Lung Cancer Patients
50%
Minimal Residual Disease
100%
Non-associated
6%
Non-small Cell Lung Cancer (NSCLC)
8%
Non-small Cell Lung Cancer Patients
75%
Optimal Timing
8%
Plasma Samples
41%
Prognostic Value
6%
Recurrence Prediction
16%
Recurrence-free Survival
29%
Recurrent Disease
8%
Residual Disease
6%
Retrospective Analysis
6%
Second Check
6%
Sequence Method
8%
Short-term Recurrence
29%
Subgroup Analysis
8%
Transferability
6%
Treatment-seeking Sample
8%
Tumor Recurrence
27%
Tumor-agnostic
68%
Pharmacology, Toxicology and Pharmaceutical Science
Biological Marker
30%
Circulating Tumor DNA
100%
Lung Cancer
50%
Minimal Residual Disease
100%
Neoplasm
71%
Non Small Cell Lung Cancer
78%
Recurrence Free Survival
30%
Recurrent Disease
32%
Tumor Recurrence
29%
Medicine and Dentistry
Biological Marker
14%
Circulating Tumor DNA
50%
DNA Determination
7%
Fisher Exact Test
14%
Log Rank Test
14%
Lung Cancer
50%
Minimal Residual Disease
50%
Neoplasm
21%
Non Small Cell Lung Cancer
28%
Recurrence Free Survival
14%
Recurrent Disease
7%
Tumor Recurrence
21%
